文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

住院COVID-19患者治疗药物的采用与去采用

Adoption and Deadoption of Medications to Treat Hospitalized Patients With COVID-19.
PubMed 文献 · Crit Care Explor · 2022-06-30
一句话结论美国多中心观察性队列显示,住院COVID-19患者用药模式随证据与政策变化可靠演变,羟氯喹在2020年6月降至近零、伊维菌素极少使用。

该观察性队列研究利用Optum去标识化理赔-临床数据集(含美国医院多中心电子健康记录),纳入2020年1月至2021年6月住院的成人COVID-19患者141,533例,分析瑞德西韦、羟氯喹、静脉糖皮质激素、托珠单抗、肝素类抗凝药和伊维菌素的使用模式。结果显示,24.4%入住ICU、10.4%需机械通气、13.4%住院期间死亡;整个研究期间糖皮质激素使用最常见(47.0%),其次为瑞德西韦(33.2%)、抗凝药(19.3%)、羟氯喹(7.3%)和托珠单抗(3.4%)。羟氯喹使用在2020年3月达峰、至2020年6月降至近零;瑞德西韦、糖皮质激素和托珠单抗的使用在大型国际试验阳性结果新闻发布后均上升。作者认为,用药模式随新证据和政策变化可靠演变,这些发现可为促进急性期治疗的最佳采用与去采用提供参考。

要点

  • 141,533例住院成人COVID-19患者中,24.4%入住ICU、10.4%需机械通气、13.4%住院期间死亡。
  • 整个研究期间用药比例:糖皮质激素47.0%、瑞德西韦33.2%、抗凝药19.3%、羟氯喹7.3%、托珠单抗3.4%、伊维菌素0.4%。
  • 羟氯喹使用在2020年3月达峰,至2020年6月降至近零。
  • 瑞德西韦、糖皮质激素和托珠单抗的使用在大型国际试验阳性结果新闻发布后均上升。
  • 伊维菌素使用在研究期间略有增加,但总体极为罕见(0.4%)。

适用人群与场景

  • 2020年1月至2021年6月住院的成人COVID-19患者,数据来自Optum去标识化理赔-临床数据集(含美国医院多中心电子健康记录)。
  • 分析覆盖全部患者及危重症与非危重症亚组。

研究设计与关键结果

  • 研究设计为观察性队列研究,数据来自Optum去标识化理赔-临床数据集(含美国医院多中心电子健康记录),纳入2020年1月至2021年6月住院的成人COVID-19患者141,533例。
  • 141,533例 eligible 患者中,34,515例(24.4%)需入住ICU,14,754例(10.4%)需机械通气,18,998例(13.4%)住院期间死亡。
  • 整个研究期间平均用药比例:糖皮质激素47.0%最常见,其次为瑞德西韦33.2%、抗凝药19.3%、羟氯喹7.3%、托珠单抗3.4%;伊维菌素总体极为罕见(0.4%)。
  • 羟氯喹使用在2020年3月达峰,至2020年6月降至近零。
  • 瑞德西韦、糖皮质激素和托珠单抗的使用在宣布大型国际试验阳性结果的新闻发布后均上升。
  • 伊维菌素使用在研究期间略有增加,但总体极为罕见(0.4%)。

证据类型、等级与局限

  • 证据类型:观察性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,这些发现可能为促进急性期治疗的最佳采用与去采用提供参考。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: The COVID-19 pandemic was characterized by rapidly evolving evidence regarding the efficacy of different therapies, as well as rapidly evolving health policies in response to that evidence. Data on adoption and deadoption are essential as we learn from this pandemic and prepare for future public health emergencies.

DESIGN: We conducted an observational cohort study in which we determined patterns in the use of multiple medications to treat COVID-19: remdesivir, hydroxychloroquine, IV corticosteroids, tocilizumab, heparin-based anticoagulants, and ivermectin. We analyzed changes both overall and within subgroups of critically ill versus Noncritically ill patients.

SETTING: Data from Optum's deidentified Claims-Clinical Dataset, which contains multicenter electronic health record data from U.S. hospitals.

PATIENTS: Adults hospitalized with COVID-19 from January 2020 to June 2021.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Of 141,533 eligible patients, 34,515 (24.4%) required admission to an ICU, 14,754 (10.4%) required mechanical ventilation, and 18,998 (13.4%) died during their hospitalization. Averaged over the entire time period, corticosteroid use was most common (47.0%), followed by remdesivir (33.2%), anticoagulants (19.3%), hydroxychloroquine (7.3%), and tocilizumab (3.4%). Usage patterns varied substantially across treatments. For example, hydroxychloroquine use peaked in March 2020 and leveled off to near zero by June 2020, whereas the use of remdesivir, corticosteroids, and tocilizumab all increased following press releases announcing positive results of large international trials. Ivermectin use increased slightly over the study period but was extremely rare overall (0.4%).

CONCLUSIONS: During the COVID-19 pandemic, medication treatment patterns evolved reliably in response to emerging evidence and changes in policy. These findings may inform efforts to promote optimal adoption and deadoption of treatments for acute care conditions.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Barbash IJ, Davis BS, Minturn JS, et al. Adoption and Deadoption of Medications to Treat Hospitalized Patients With COVID-19. Crit Care Explor. 2022. PMID: 35923589. doi:10.1097/CCE.0000000000000727

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。